# Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients

> **NCT01352208** · PHASE1,PHASE2 · TERMINATED · sponsor: **Astellas Pharma Inc** · enrollment: 13 (actual)

## Conditions studied

- Castrate Resistant Prostate Cancer

## Interventions

- **DRUG:** ASP9521

## Key facts

- **NCT ID:** NCT01352208
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-03
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** It was decided to discontinue the development in consideration of the results of a P1 study
- **Last updated:** 2014-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01352208

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01352208, "Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01352208. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*